Protein Tyrosine Phosphatase Gene PTPN22 Polymorphism in Psoriasis: Lack of Evidence for Association  by Nistor, Ioana et al.
Protein Tyrosine Phosphatase Gene PTPN22 Polymorphism in
Psoriasis: Lack of Evidence for Association
To the Editor:
LYP, the protein product of the protein tyrosine phosphatase
gene PTPN22 located on human chromosome 1p13.2, is
involved in downregulation of T cell signaling through its
interaction with C-terminal Src tyrosine kinase (Csk) (Clout-
ier and Veillette, 1996), by phosphorylation of regulatory ty-
rosines on the Src family kinase Lck (Cloutier and Veillette,
1999). A missense mutation of this gene (C1858T, R620W),
found in 15%–17% of the Caucasian population, has been
associated with autoimmune pathology in type I diabetes
(T1D) (Bottini et al, 2004; Onengut-Gumuscu et al, 2004;
Smyth et al, 2004; Ladner et al, 2005), rheumatoid arthritis
(RA) (Begovich et al, 2004), systemic lupus erythematosus
(SLE) (Kyogoku et al, 2004), and Graves disease (GD)
(Smyth et al, 2004; Velaga et al, 2004) but not in multiple
sclerosis (Begovich et al, 2005). It has also been shown to
be functionally relevant in terms of binding to Csk (Bottini
et al, 2004) and inhibition of signalling via the T cell antigen
receptor (Begovich et al, 2004).
Although no genome-wide search has identified human
chromosome 1p13.2 as a psoriasis susceptibility locus, the
widely accepted concept that psoriasis is mediated at least
in part by activated T cells (Lew et al, 2004; Sugiyama et al,
2005) suggests PTPN22 as a prime target for candidate
gene testing in psoriasis. In this study, we investigated as-
sociation of the PTPN22 C1858T polymorphism in our col-
lection of 517 families containing 1,146 affected individuals.
This study was carried out in accordance with the Principles
of Helsinki and was approved by the ethical boards of the
University of Michigan, the University of Kiel, and the Henry
Ford Health System. Written informed consent was ob-
tained from all subjects. Genomic DNA was amplified using
primers flanking the C1858T variation and the polymorph-
isms were scored using the SnapShot SNP assay reagents
and GeneMapper software (Applied Biosystems, Foster
City, California). Three different statistical tests were applied
to the data: the transmission/disequilibrium test (TDT)
(Spielman et al, 1993), the pedigree disequilibrium test
(PDT) (Martin et al, 2000, 2001), and the family-based as-
sociation test (FBAT) (Rabinowitz and Laird, 2000; Horvath
et al, 2001, 2004). All three methods were implemented as
biallelic two-sided tests of the null hypothesis of no asso-
ciation in the presence of linkage. For the TDT, a single trio
was randomly extracted from each pedigree, as recom-
mended by Spielman and Ewens (1996). Since results vary
depending upon the particular random selection, the anal-
ysis was repeated 999 times with different random number
seeds, and the median result was reported. In the FBAT, we
used with the empirical variance and an offset of 0 (i.e.,
unaffecteds do not contribute to the test statistic but do aid
inference of parental genotypes).
As shown in Table I, none of these three methods yielded
significant evidence for association. This outcome ap-
peared to be because of a lack of association, rather than
a lack of statistical power. As shown in Table I, measures of
LD show only a weak negative association of the minor (T)
allele with psoriasis (47.3% transmission, D ¼ 0:072) that
differ little from the expected values of 50% transmission
and D ¼ 0 under the null hypothesis of no association.
Power calculations, performed by the first approximation
method of Knapp (1999) (Table II), revealed excellent power
of the TDT to detect association under all models except
recessive, a model that is not supported for PTPN22 in T1D
(Smyth et al, 2004), RA (Begovich et al, 2004), SLE (Kyogoku
et al, 2004), or GD (Velaga et al, 2004). Our sample, how-
ever, would probably not detect an association with pso-
riasis if PTNP22 does indeed act in a recessive fashion as a
psoriasis locus or if the genetic effect of PTPN22 under
other models is weak (GRR1 o1.56 for a dominant model,
GRR1 o1.50 for an additive model, and GRR1 o1.47 for a
multiplicative model).
It seems unlikely that our negative results are due to ge-
netic heterogeneity, as the frequency of the T allele among our
founder chromosomes was similar to Caucasian control pop-
ulations in previous studies (0.1087 for 2669 founder chromo-
somes in this study, as compared with 0.0864 for 3922 pooled
control chromosomes in SLE (Kyogoku et al, 2004) and 0.104
for 3,436 control chromosomes in T1D (Smyth et al, 2004).
While this article was under review, a report appeared
finding no association of the PTPN22 R620W polymorphism
with psoriasis in a study of families with multiple autoim-
mune diseases (Criswell et al, 2005). This study had very
little power to detect association of the PTPN22 R620W
polymorphism with psoriasis as its sample of 265 multiple
autoimmune disease families contained only 63 psoriatics.
Based on these results, we conclude that C1858T po-
lymorphism of PTPN22 is unlikely to be associated in pso-
riasis. Similar negative results have recently been reported
for multiple sclerosis (Begovich et al, 2005), indicating that
the PTPN22 R620W variation is unlikely to be universally
associated with autoimmune disease. Additional family-
based and case–control association studies in psoriasis
and other immunologically mediated disorders will clarify
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the spectrum of disorders associated with this functional
polymorphism, which may ultimately serve as an important
molecular classifier of autoimmune disease.
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Table I. Results of family-based tests of the association of psoriasis with the T allele of the C1858T (R620W)
polymorphism of the PTPN22 gene
TDT PDT FBAT
# fama # inf famb T:NTc p-valued # fama # inf famb De p-valued # fama # inf famb Zf p-valued
469 182 88:98 0.51 505 194 0.072 0.51 517 176 1.66 0.097
aThe number of families shown for each association test counts only those families with at least one typed and phenotypically informative unit. For the
TDT, this unit is a trio (an affected child and both parents), for the PDT, it is a trio or a discordant sibpair (an affected and unaffected sib), and for the FBAT,
with the settings used it is a trio, discordant sibpair, or a sibship with three or more affected sibs.
bThe number of informative families is the subset of the typed and phenotypically informative families that are genotypically informative for the allele
being tested.
cT:NT is the ratio of transmissions to non-transmissions of the test allele from heterozygous parents to affected children in the TDT.
dAll p-values are uncorrected for multiple testing.
eD is a standardized measure of marker-trait disequilibrium for the PDT which has been described by us previously (Collaboration, 2005).
fLarge sample test statistic for association, distributed as a standard normal.
TDT, transmission/disequilibrium test; PDT, pedigree disequilibrium test; FBAT, family-based association test.
Table II. Genotype relative risks for putative disease allele
heterozygotes (GRR1) and homozygotes (GRR2) needed to
achieve power of 0.80 and 0.95 when using the TDT (and a type I
error rate of 0.05) to test for association of psoriasis and the T
allele of the C1858T (R620W) polymorphism of the PTPN22 gene
Model of inheritance
GRR2/GRR1 for
80% power
GRR2/GRR1 for
95% power
Dominant 1.56/1.56 1.75/1.75
Additive 1.99/1.50 2.34/1.67
Multiplicative 2.17/1.47 2.65/1.63
Recessive 5.44/— 7.02/—
TDT, transmission/disequilibrium test.
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